Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Real-time Estimate Cboe BZX  -  01:36 2022-09-29 pm EDT
39.92 USD   -3.27%
09/15Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
09/12Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
AQ
09/09Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : Ultragenyx Pharmaceutical Inc., Q2 2022 Earnings Call, Jul 28, 2022

07/28/2022 | 05:00pm EDT
Good afternoon, and welcome to the Ultragenyx Second Quarter Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn today's call over to Joshua Higa, Executive...


© S&P Capital IQ 2022
All news about ULTRAGENYX PHARMACEUTICAL INC.
09/15Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
09/12Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
AQ
09/09Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
GL
09/09Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
GL
09/07Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi's 17th Annual Bi..
CI
09/01Ultragenyx to Participate at Citi BioPharma Conference
GL
09/01Ultragenyx to Participate at Citi BioPharma Conference
AQ
08/23Goldman Sachs Adjusts Price Target on Ultragenyx Pharmaceutical to $74 From $72, Reiter..
MT
08/18Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
08/17Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2022 401 M - -
Net income 2022 -555 M - -
Net cash 2022 858 M - -
P/E ratio 2022 -5,45x
Yield 2022 -
Capitalization 2 890 M 2 890 M -
EV / Sales 2022 5,06x
EV / Sales 2023 5,42x
Nbr of Employees 1 119
Free-Float 95,0%
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 41,27 $
Average target price 111,71 $
Spread / Average Target 171%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Mardi C. Dier Chief Financial Officer & Executive Vice President
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-50.92%2 890
GILEAD SCIENCES, INC.-11.95%80 128
REGENERON PHARMACEUTICALS, INC.11.70%75 415
VERTEX PHARMACEUTICALS33.16%74 991
BIONTECH SE-48.10%32 514
WUXI APPTEC CO., LTD.-40.29%28 423